Funding Clinical Trials

Our Agency funds clinical trials testing promising stem cell or gene therapies for currently incurable diseases or disorders to help patients with unmet medical needs. For basic information about stem cell trials, visit our Clinical Trials 101 page. For a list of clinical trials that are a result of early-stage CIRM grants click here.

108

CIRM-FUNDED CLINICAL TRIALS

Disease AreasInvestigatorOrganizationPhaseTrial StatusTarget EnrollmentDetail
B cell cancers
Leukemia
Thomas J Kipps University of California, San Diego Phase 1/2 Active, not recruiting 102
Pediatrics
Sickle Cell Disease
Dr. Doanld B Kohn University of California, Los Angeles Phase 1 Active, not recruiting 4
HIV-related Lymphoma
HIV/AIDS
Dr Mehrdad Abedi University of California, Davis Phase 1/2 Active, not recruiting 11
HIV/AIDS Prof. John A Zaia City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 12
Kidney Failure Dr Robert Lowsky Stanford University Phase 1 Active, not recruiting 15
Kidney Failure Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 240
Brain Cancer Dr. Christine E. Brown City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 82
Blood Cancer
Bone Marrow Transplant and Viral Infection
Michael A. Pulsipher Children’s Hospital of Los Angeles Phase 1/2 Active, not recruiting 60
Sickle Cell Disease Dr. De-Fu Zeng City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 3
B cell cancers
Leukemia
Dr. David B. Miklos Stanford University Phase 1 Active, not recruiting 56
Lung Cancer Steven M. Dubinett University of California, Los Angeles Phase 1 Active, not recruiting 24
Cystinosis
Kidney Failure
Dr. Stephanie Cherqui University of California, San Diego Phase 1/2 Active, not recruiting 6
Parkinson's Disease Krystof S. Bankiewicz Brain Neurotherapy Bio Phase 1 Active, not recruiting 11
HIV/AIDS William Kennedy Excision BioTherapeutics Phase 1 Active, not recruiting 6
Melanoma Robert Dillman Caladrius Biosciences Phase 3 Closed 4
Type 1 diabetes Howard Foyt ViaCyte, Inc. Phase 1/2 Closed 19
Melanoma
Skin cancer
Dr. Antoni Ribas MD/PhD University of California, Los Angeles Phase 1 Closed 5
Heart failure Dr. Rachel Ruckdeschel Smith Capricor, Inc Phase 2 Closed 135
Leukemia, Acute Myeloid (AML) Dr. Colleen Delaney Nohla Therapeutics Inc Phase 2 Closed 146
Leukemia, Acute Myeloid (AML) Mark Chao Forty Seven Inc. Phase 1 Closed 258
Multiple Myeloma Rajesh Belani MD Poseida Therapeutics, Inc. Phase 1 Closed 105
Sarcoma Theodore Scott Nowicki University of California, Los Angeles Phase 1 Closed 5
Bone or Cartilage Disease Dr. Gayatri Rao Rocket Pharmaceuticals, Inc. Phase 1 Closed 1
B cell cancers Dr. Paul Finnegan Angiocrine Bioscience, Inc. Phase 3 Closed 130
Blood Cancer Dr. Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 10
Amyotrophic Lateral Sclerosis Dr. Ralph Kern BrainStorm Cell Therapeutics Phase 3 Completed 196
Spinal Cord Injury Dr. Jane Stephanie Lebkowski Dr. Geron Corporation Phase 1 Completed 5
Huntington's Disease Dr. Vicki Wheelock University of California, Davis Phase 1/2 Completed 29
Spinal Cord Injury Francois Binette Lineage Cell Therapeutics, Inc. Phase 1/2 Completed 25
Stroke Dr. Bijan Nejadnik SanBio, Inc. Phase 2 Completed 163
Amyotrophic Lateral Sclerosis Professor Clive Niels Svendsen Cedars-Sinai Medical Center Phase 1/2 Completed 18
Retinitis Pigmentosa Dr. Henry John Klassen University of California, Irvine Phase 1/2 Completed 28
Retinitis Pigmentosa Henry John Klassen jCyte, Inc Phase 2 Completed 84
Genetic Disorder
Immune Disease
Pediatrics
Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)
Dr. Donald B Kohn
Leslie Meltzer
Dr. Doanld B Kohn
University of California, Los Angeles
Orchard Therapeutics plc
Phase 2 Completed 10
HIV/AIDS Geoff Symonds Calimmune, Inc. Phase 1/2 Completed 13
Blood Cancer Thomas J Kipps University of California, San Diego Phase 1 Completed 26
Blood Cancer
Solid Tumors
Dr. Irving L Weissman MD Stanford University Phase 1 Completed 88
Solid Tumors Dr. Dennis J Slamon University of California, Los Angeles Phase 1 Completed 46
Colon Cancer Mark Chao Forty Seven Inc. Phase 1/2 Completed 78
Osteonecrosis Nancy E. Lane University of California, Davis Phase 1/2 Completed 58
Pulmonary Hypertension
Vascular Disease
Dr. Michael I Lewis Cedars-Sinai Medical Center Phase 1/2 Completed 26
Type 1 diabetes Dr. William Sietsema Caladrius Biosciences Phase 2 Completed 113
Heart disease associated with Duchenne muscular dystrophy Dr. Linda Marban Capricor, Inc Phase 2 Completed 25
Kidney Failure Jeffrey Lawson Humacyte, Inc. Phase 3 Completed 355
Type 1 diabetes Manasi Jaiman ViaCyte, Inc. Phase 1/2 Completed 49
Arthritis
Osteoarthritis
Dr. Kristen A Johnson Calibr Phase 1 Completed 60
Kidney Failure Daniel Brennan Medeor Therapeutics, Inc. Phase 3 Completed 30
Beta Thalassemia Bettina Cockroft Sangamo BioSciences, Inc. Phase 1/2 Completed 5
Blood Cancer Dr. Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1/2 Completed 42
Immune Disease
Leukocyte Adhesion Deficiency
Dr. Kinnari Patel Rocket Pharmaceuticals, Inc. Phase 1/2 Completed 9
Retinitis Pigmentosa Henry John Klassen jCyte, Inc Phase 2 Completed 84
COVID-19 Dr. Michael Matthay MD University of California, San Francisco Phase 2 Completed 120
Alpha Thalassemia Major Dr. Tippi C. MacKenzie MD University of California, San Francisco Phase 1 Enrolling by invitation 10
Anemia Dr. Matthew H Porteus Stanford University Phase 1/2 Launching N/A
COVID-19
Respiratory Disorders
Prof. John A Zaia City of Hope, Beckman Research Institute Phase 1 Launching N/A
Amyotrophic Lateral Sclerosis Clive Svendsen Cedars-Sinai Medical Center Phase 1 Launching N/A
Brain Cancer Dr Jana Portnow City of Hope, Beckman Research Institute Phase 1 Launching N/A
Anemia
Bone Marrow Transplant and Viral Infection
Alice Bertaina Stanford University Phase 1/2 Launching N/A
Colon Cancer Ivan King Tachyon Therapeutics, Inc Phase 1 Launching N/A
Bone or Cartilage Disease
Hearing Loss
Intellectual Disability
Metabolic Disorders
Vision Loss
Dr Robert Hayes Immusoft Corporation Phase 1 Launching N/A
Osteoarthritis Dr. Thomas W Chalberg Jr. Genascence Corporation Phase 1 Launching N/A
Solid Tumors Pei Wang Eureka Therapeutics, Inc. Phase 1/2 Launching N/A
Corneal Damage R. Kim Brazzell Combangio, Inc. Phase 2 Launching N/A
Anemia Ryotaro Nakamura City of Hope, Beckman Research Institute Phase 1 Launching N/A
HIV/AIDS Dr. Angelo Manuel Almeida Cardoso Ph.D., MD City of Hope, Beckman Research Institute Phase 1 Launching N/A
Leukemia, Acute Myeloid (AML) Elizabeth Budde City of Hope, Beckman Research Institute Phase 1 Launching N/A
Age-related macular degeneration Dr Jane S Lebkowski Regenerative Patch Technologies LLC Phase 2 Launching N/A
Brain Cancer Dr. Reena Parada Thomas Stanford University Phase 1 Launching N/A
Neurological Disorders Amit Etkin Alto Neuroscience Phase 2 Launching N/A
Neurological Disorders
Other
Prof. Olivia Kim-McManus University of California, San Diego Phase 1/2 Launching N/A
Melanoma Anusha Kalbasi Stanford University Phase 1 Launching N/A
Parkinson's Disease Dr. Edward Wirth III Aspen Neuroscience Phase 1 Launching N/A
Immune Disease DR Jonathan Benjamin ImmPACT-Bio, Inc. Phase 1/2 Launching N/A
Brain Cancer Dr. Hideho Okada University of California, San Francisco Phase 1 Launching N/A
Lupus, Systemic Lupus Erythematosus (SLE) Barbara Hickingbottom Fate Therapeutics, Inc. Phase 1 Launching N/A
Brain Cancer Noriyuki Kasahara University of California, San Francisco Phase 1 Launching N/A
Age-related macular degeneration Dr. Jeffrey H Stern Luxa Biotechnology Phase 1/2 Launching N/A
Solid Tumors Dr. John Le Gall Allogene Therapeutics Phase 1 Launching N/A
Sickle Cell Disease Mark C. Walters M.D. University of California, San Francisco Phase 1 Not yet recruiting 9
Bladder or Urinary Tract Disorder James Yoo Wake Forest University Health Sciences Phase 1 Not yet recruiting 10
Immune Disease
Pediatrics
X-linked Chronic Granulomatous Disease
Dr. Doanld B Kohn University of California, Los Angeles Phase 1/2 Recruiting 16
Immune Disease
Pediatrics
Severe Combined Immunodeficiency, X-linked (X-SCID)
Dr. Judith A Shizuru
Wendy Pang
Stanford University
Jasper Therapeutics, Inc.
Phase 1/2 Recruiting 40
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) Mort Cowan University of California, San Francisco Phase 1 Recruiting 25
Kidney Failure Dr. Everett H. Meyer Stanford University Phase 1 Recruiting 22
Type 1 diabetes Peter Stock University of California, San Francisco Phase 1/2 Recruiting 8
Brain Cancer
Breast Cancer
Dr Saul J Priceman City of Hope, Beckman Research Institute Phase 1 Recruiting 39
Corneal Damage Dr. Sophie X Deng University of California, Los Angeles Phase 1 Recruiting 20
Retinitis Pigmentosa Clive Svendsen Cedars-Sinai Medical Center Phase 1 Recruiting 16
HIV/AIDS
Immune Disease
Steven G. Deeks University of California, San Francisco Phase 1/2 Recruiting 18
Developmental Disorders
Spina Bifida
Dr. Diana L. Farmer University of California, Davis Phase 2 Recruiting 55
Sickle Cell Disease David Williams Boston Children’s Hospital Phase 2 Recruiting 25
Brain Cancer Dr. Leo D Wang City of Hope, Beckman Research Institute Phase 1 Recruiting 18
Leukemia, Acute Myeloid (AML) Joseph Paul Woodard Immune-Onc Therapeutics Phase 1 Recruiting 106
Stroke Dr. Gary Steinberg Stanford University Phase 1 Recruiting 30
Brain Cancer Crystal Mackall Stanford University Phase 1 Recruiting 54
B cell cancers
Leukemia
Leukemia, Acute Myeloid (AML)
Dr. Matthew H Porteus Stanford University Phase 1 Recruiting 22
Heart failure Dr. Joseph C. Wu Stanford University Phase 1 Recruiting 18
IPEX Syndrome Dr. Rosa Bacchetta Stanford University Phase 1 Recruiting 30
Solid Tumors Dr. Pamela Reilly Contag BioEclipse Therapeutics INC. Phase 1 Recruiting 60
Epilepsy Dr. Cory R Nicholas Neurona Therapeutics Phase 1 Recruiting 40
Muscle Injury Peter C Belafsky University of California, Davis Phase 1/2 Recruiting 62
Immune Disease
Severe Combined Immunodeficiency, X-linked (X-SCID)
Stephen Gottschalk St. Jude Children’s Research Hospital Phase 1/2 Suspended 28
Brain Cancer Anthony J. Gringeri ImmunoCellular Therapeutics Phase 3 Suspended 234
Age-related macular degeneration Dr. Mark S Humayun University of Southern California Phase 1 Unknown status 16
COVID-19
Respiratory Disorders
William van der Touw Celularity Inc. Phase 1/2 Unknown status 86
Sickle Cell Disease Dr Pierre Caudrelier ExCellThera Inc. Phase 1 Withdrawn N/A